Endocrine disrupting compounds and prostate cancer

Cancer Lett. 2006 Sep 8;241(1):1-12. doi: 10.1016/j.canlet.2005.10.006. Epub 2005 Nov 17.

Abstract

Prostate cancer is a major health concern and is treated based on its hormone dependence. Agents that alter hormone action can have substantial biological effects on prostate cancer development and progression. As such, there is significant interest in uncovering the potential effects of endocrine disrupting compound (EDC) exposure on prostate cancer. The present review is focused on agents that alter hormone action in the prostate and how they may impact cancer growth or treatment.

Publication types

  • Review

MeSH terms

  • Androgens / physiology
  • Diet
  • Endocrine Disruptors / administration & dosage
  • Endocrine Disruptors / toxicity*
  • Humans
  • Male
  • Mutagens
  • Prostate / growth & development
  • Prostatic Neoplasms / chemically induced*
  • Prostatic Neoplasms / physiopathology
  • Receptors, Androgen / physiology

Substances

  • Androgens
  • Endocrine Disruptors
  • Mutagens
  • Receptors, Androgen